Regeneron Pharmaceuticals (NASDAQ:REGN) Sets New 1-Year Low – Should You Sell?

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) reached a new 52-week low during trading on Thursday . The stock traded as low as $712.30 and last traded at $714.62, with a volume of 907724 shares trading hands. The stock had previously closed at $740.01.

Analyst Ratings Changes

A number of research analysts have weighed in on REGN shares. BMO Capital Markets decreased their price objective on Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating on the stock in a report on Friday, November 1st. Wolfe Research assumed coverage on shares of Regeneron Pharmaceuticals in a research note on Friday, November 15th. They set an “outperform” rating and a $1,150.00 price objective for the company. Leerink Partners reissued a “market perform” rating and issued a $1,077.00 target price (down from $1,175.00) on shares of Regeneron Pharmaceuticals in a research note on Tuesday, September 24th. Morgan Stanley dropped their price target on Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating for the company in a research report on Friday, November 1st. Finally, Truist Financial reduced their price objective on Regeneron Pharmaceuticals from $1,137.00 to $1,126.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. One research analyst has rated the stock with a sell rating, six have issued a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $1,052.90.

Regeneron Pharmaceuticals Trading Down 3.4 %

The company has a 50 day moving average of $833.09 and a 200-day moving average of $998.86. The stock has a market cap of $78.53 billion, a price-to-earnings ratio of 17.68, a price-to-earnings-growth ratio of 2.19 and a beta of 0.08. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28.

Institutional Trading of Regeneron Pharmaceuticals

Hedge funds have recently made changes to their positions in the business. DGS Capital Management LLC boosted its position in Regeneron Pharmaceuticals by 13.8% in the 3rd quarter. DGS Capital Management LLC now owns 429 shares of the biopharmaceutical company’s stock valued at $451,000 after buying an additional 52 shares during the period. Oddo BHF Asset Management Sas acquired a new stake in shares of Regeneron Pharmaceuticals in the third quarter valued at $1,598,000. American Trust purchased a new position in Regeneron Pharmaceuticals in the third quarter valued at $600,000. Synovus Financial Corp grew its stake in Regeneron Pharmaceuticals by 3.4% during the 3rd quarter. Synovus Financial Corp now owns 1,881 shares of the biopharmaceutical company’s stock worth $1,977,000 after purchasing an additional 61 shares in the last quarter. Finally, Tidal Investments LLC increased its holdings in Regeneron Pharmaceuticals by 8.7% during the 3rd quarter. Tidal Investments LLC now owns 6,350 shares of the biopharmaceutical company’s stock worth $6,675,000 after purchasing an additional 510 shares during the period. Institutional investors and hedge funds own 83.31% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.